General Counsel & Chief Operating Officer · PMV Pharmaceuticals, Inc. (PMVP)

Robert Ticktin

FY2025 is the first fiscal year CompBrief holds for Robert Ticktin as a named executive officer of PMV Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$861,206

Salary $450,000Stock awards $0

3rd of 3 named executive officers at PMV Pharmaceuticals by FY2025 total.

3 named officers on file for PMV Pharmaceuticals, FY2025

Robert Ticktin’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • PMVP’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how PMV Pharmaceuticals’s whole pay program stands against its peers

  • PMV Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PMVP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2026 (DEF 14A).

Free

Get Robert Ticktin’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Robert Ticktin compensation by year

PMV Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as PMV Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$450,000
Bonus$0
Stock awards$0
Option awards$249,206
Non-equity incentive$162,000
Pension and deferred compensation$0
All other$0
Total$861,206

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PMV Pharmaceuticals, Inc. DEF 14A filed April 22, 2026, accession 0001140361-26-016038, and prior-year filings. Open the filing on EDGAR.

How this page was built: the PMV Pharmaceuticals, Inc. filed document, accession 0001140361-26-016038. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option215,313—$1.32
Option87,928—$1.80
Option57,988—$1.48
Option61,334—$1.48

Per the Outstanding Equity Awards at Fiscal Year-End table in PMV Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

PMV Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
David MackPresident, Chief Executive Officer and Director$1,665,191
Deepika JalotaChief Development Officer$935,187
Robert Ticktin · this pageGeneral Counsel & Chief Operating Officer$861,206

The full PMV Pharmaceuticals compensation record

free company brief

This page is one person within PMV Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the PMV Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PMV Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Robert Ticktin's compensation dossier · One-time report. No refunds.